BACKGROUND: Bone metastases are a major cause of morbidity and mortality in men with prostate cancer. Preclinical studies suggest that osteoclast inhibition might prevent bone metastases. We assessed denosumab, a fully human anti-RANKL monoclonal antibody, for prevention of bone metastasis or death in non-metastatic castration-resistant prostate cancer. METHODS: In this phase 3, double-blind, randomised, placebo-controlled study, men with non-metastatic castration-resistant prostate cancer at high risk of bone metastasis (prostate-specific antigen [PSA] ≥8·0 μg/L or PSA doubling time ≤10·0 months, or both) were enrolled at 319 centres from 30 countries. Patients were randomly assigned (1:1) via an interactive voice response system to receive subcutaneous denosumab 120 mg or subcutaneous placebo every 4 weeks. Randomisation was stratified by PSA eligibility criteria and previous or ongoing chemotherapy for prostate cancer. Patients, investigators, and all people involved in study conduct were masked to treatment allocation. The primary endpoint was bone-metastasis-free survival, a composite endpoint determined by time to first occurrence of bone metastasis (symptomatic or asymptomatic) or death from any cause. Efficacy analysis was by intention to treat. The masked treatment phase of the trial has been completed. This trial was registered at ClinicalTrials.gov, number NCT00286091. FINDINGS:1432 patients were randomly assigned to treatment groups (716 denosumab, 716 placebo). Denosumab significantly increased bone-metastasis-free survival by a median of 4·2 months compared with placebo (median 29·5 [95% CI 25·4-33·3] vs 25·2 [22·2-29·5] months; hazard ratio [HR] 0·85, 95% CI 0·73-0·98, p=0·028). Denosumab also significantly delayed time to first bone metastasis (33·2 [95% CI 29·5-38·0] vs 29·5 [22·4-33·1] months; HR 0·84, 95% CI 0·71-0·98, p=0·032). Overall survival did not differ between groups (denosumab, 43·9 [95% CI 40·1-not estimable] months vs placebo, 44·8 [40·1-not estimable] months; HR 1·01, 95% CI 0·85-1·20, p=0·91). Rates of adverse events and serious adverse events were similar in both groups, except for osteonecrosis of the jaw and hypocalcaemia. 33 (5%) patients on denosumab developed osteonecrosis of the jaw versus none on placebo. Hypocalcaemia occurred in 12 (2%) patients on denosumab and two (<1%) on placebo. INTERPRETATION: This large randomised study shows that targeting of the bone microenvironment can delay bone metastasis in men with prostate cancer. FUNDING: Amgen Inc.
RCT Entities:
BACKGROUND:Bone metastases are a major cause of morbidity and mortality in men with prostate cancer. Preclinical studies suggest that osteoclast inhibition might prevent bone metastases. We assessed denosumab, a fully human anti-RANKL monoclonal antibody, for prevention of bone metastasis or death in non-metastatic castration-resistant prostate cancer. METHODS: In this phase 3, double-blind, randomised, placebo-controlled study, men with non-metastatic castration-resistant prostate cancer at high risk of bone metastasis (prostate-specific antigen [PSA] ≥8·0 μg/L or PSA doubling time ≤10·0 months, or both) were enrolled at 319 centres from 30 countries. Patients were randomly assigned (1:1) via an interactive voice response system to receive subcutaneous denosumab 120 mg or subcutaneous placebo every 4 weeks. Randomisation was stratified by PSA eligibility criteria and previous or ongoing chemotherapy for prostate cancer. Patients, investigators, and all people involved in study conduct were masked to treatment allocation. The primary endpoint was bone-metastasis-free survival, a composite endpoint determined by time to first occurrence of bone metastasis (symptomatic or asymptomatic) or death from any cause. Efficacy analysis was by intention to treat. The masked treatment phase of the trial has been completed. This trial was registered at ClinicalTrials.gov, number NCT00286091. FINDINGS: 1432 patients were randomly assigned to treatment groups (716 denosumab, 716 placebo). Denosumab significantly increased bone-metastasis-free survival by a median of 4·2 months compared with placebo (median 29·5 [95% CI 25·4-33·3] vs 25·2 [22·2-29·5] months; hazard ratio [HR] 0·85, 95% CI 0·73-0·98, p=0·028). Denosumab also significantly delayed time to first bone metastasis (33·2 [95% CI 29·5-38·0] vs 29·5 [22·4-33·1] months; HR 0·84, 95% CI 0·71-0·98, p=0·032). Overall survival did not differ between groups (denosumab, 43·9 [95% CI 40·1-not estimable] months vs placebo, 44·8 [40·1-not estimable] months; HR 1·01, 95% CI 0·85-1·20, p=0·91). Rates of adverse events and serious adverse events were similar in both groups, except for osteonecrosis of the jaw and hypocalcaemia. 33 (5%) patients on denosumab developed osteonecrosis of the jaw versus none on placebo. Hypocalcaemia occurred in 12 (2%) patients on denosumab and two (<1%) on placebo. INTERPRETATION: This large randomised study shows that targeting of the bone microenvironment can delay bone metastasis in men with prostate cancer. FUNDING: Amgen Inc.
Authors: James Mohler; Robert R Bahnson; Barry Boston; J Erik Busby; Anthony D'Amico; James A Eastham; Charles A Enke; Daniel George; Eric Mark Horwitz; Robert P Huben; Philip Kantoff; Mark Kawachi; Michael Kuettel; Paul H Lange; Gary Macvicar; Elizabeth R Plimack; Julio M Pow-Sang; Mack Roach; Eric Rohren; Bruce J Roth; Dennis C Shrieve; Matthew R Smith; Sandy Srinivas; Przemyslaw Twardowski; Patrick C Walsh Journal: J Natl Compr Canc Netw Date: 2010-02 Impact factor: 11.908
Authors: Mette Nørgaard; Annette Østergaard Jensen; Jacob Bonde Jacobsen; Kara Cetin; Jon P Fryzek; Henrik Toft Sørensen Journal: J Urol Date: 2010-05-16 Impact factor: 7.450
Authors: N Sathiakumar; E Delzell; M A Morrisey; C Falkson; M Yong; V Chia; J Blackburn; T Arora; M L Kilgore Journal: Prostate Cancer Prostatic Dis Date: 2011-03-15 Impact factor: 5.554
Authors: Alison T Stopeck; Allan Lipton; Jean-Jacques Body; Guenther G Steger; Katia Tonkin; Richard H de Boer; Mikhail Lichinitser; Yasuhiro Fujiwara; Denise A Yardley; María Viniegra; Michelle Fan; Qi Jiang; Roger Dansey; Susie Jun; Ada Braun Journal: J Clin Oncol Date: 2010-11-08 Impact factor: 44.544
Authors: Joel B Nelson; William Love; Joseph L Chin; Fred Saad; Claude C Schulman; Darryl J Sleep; Jiang Qian; Joyce Steinberg; Michael Carducci Journal: Cancer Date: 2008-11-01 Impact factor: 6.860
Authors: Julie R Gralow; J Sybil Biermann; Azeez Farooki; Monica N Fornier; Robert F Gagel; Rashmi N Kumar; Charles L Shapiro; Andrew Shields; Matthew R Smith; Sandy Srinivas; Catherine H Van Poznak Journal: J Natl Compr Canc Netw Date: 2009-06 Impact factor: 11.908
Authors: José Ángel Arranz Arija; Javier Cassinello Espinosa; Miguel Ángel Climent Durán; Fernando Rivero Herrero Journal: Clin Transl Oncol Date: 2012-07 Impact factor: 3.405
Authors: Alberto Bedogni; Giorgia Saia; Giordana Bettini; Anita Tronchet; Andrea Totola; Giorgio Bedogni; Paolo Tregnago; Maria Teresa Valenti; Francesco Bertoldo; Giuseppe Ferronato; Pier Francesco Nocini; Stella Blandamura; Luca Dalle Carbonare Journal: Oncologist Date: 2012-06-20
Authors: Rafael Scaf de Molon; Simon Cheong; Olga Bezouglaia; Sarah M Dry; Flavia Pirih; Joni Augusto Cirelli; Tara L Aghaloo; Sotirios Tetradis Journal: Bone Date: 2014-08-02 Impact factor: 4.398
Authors: Jian Yu Xu; William A Murphy; Denái R Milton; Camilo Jimenez; Sarika N Rao; Mouhammed Amir Habra; Steven G Waguespack; Ramona Dadu; Robert F Gagel; Anita K Ying; Maria E Cabanillas; Steven P Weitzman; Naifa L Busaidy; Rena V Sellin; Elizabeth Grubbs; Steven I Sherman; Mimi I Hu Journal: J Clin Endocrinol Metab Date: 2016-09-23 Impact factor: 5.958
Authors: Matthew R Smith; Fred Saad; Stephane Oudard; Neal Shore; Karim Fizazi; Paul Sieber; Bertrand Tombal; Ronaldo Damiao; Gavin Marx; Kurt Miller; Peter Van Veldhuizen; Juan Morote; Zhishen Ye; Roger Dansey; Carsten Goessl Journal: J Clin Oncol Date: 2013-09-16 Impact factor: 44.544